Core Insights - Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has presented cautious expectations for 2026, indicating significant internal changes are planned [2] - The company revised its 2025 organic revenue growth forecast down to 4.00% from 4.50% due to weaker demand in Latin America and emerging European markets, although overall revenue growth estimates remained stable due to favorable currency impacts [2] - Management cited last-minute cancellations of distributor orders from the Middle East and Eastern Europe as a key factor affecting performance [2] Company Ratings and Price Targets - Bernstein raised its price target for Zimmer Biomet Holdings from $97.00 to $99.00 while maintaining a 'Market Perform' rating, noting improving clarity in macro and policy uncertainties for U.S. healthcare stocks [2] - JPMorgan maintained a 'Neutral' rating on the company with a $100 price target, viewing 2026 as a pivotal year with growth opportunities while fundamentals remain strong [2] Business Focus - Zimmer Biomet Holdings, Inc. specializes in designing, manufacturing, and marketing orthopedic, spine, dental, and surgical products globally [2]

Core Insights - Medtronic reported strong financial results for Q4 and FY25, with notable growth in key franchises such as Pulsed Field Ablation, TAVR, and Diabetes [1][3][12] Q4 Financial Results - Q4 worldwide revenue reached $8.927 billion, marking a 3.9% increase as reported and 5.4% on an organic basis [6][7] - Q4 GAAP operating profit was $1.436 billion, a 36% increase, with an operating margin of 16.1%, up 380 basis points [6][7] - Non-GAAP diluted EPS for Q4 was $1.62, an 11% increase, while GAAP diluted EPS was $0.82, up 67% [7][8] FY25 Financial Results - FY25 worldwide revenue totaled $33.537 billion, a 3.6% increase as reported and 4.9% on an organic basis [9][10] - FY25 GAAP operating profit was $5.955 billion, a 16% increase, with an operating margin of 17.8%, up 190 basis points [9][10] - Non-GAAP diluted EPS for FY25 was $5.49, a 6% increase, while GAAP diluted EPS was $3.61, up 31% [10] Key Business Segments - The Cardiovascular Portfolio generated FY25 revenue of $12.481 billion, a 5.5% increase as reported and 6.3% organic [13] - The Neuroscience Portfolio reported FY25 revenue of $9.846 billion, a 4.7% increase reported and 5.2% organic [14] - The Medical Surgical Portfolio had FY25 revenue of $8.407 billion, showing a slight decrease of 0.1% reported but an increase of 0.8% organic [15] Diabetes Business Separation - Medtronic announced plans to separate its Diabetes business into a standalone public company, expected to be completed within 18 months [19] Dividend Increase - The company declared a dividend increase to $0.71 per share for Q1 FY26, marking the 48th consecutive year of dividend increases [22] Guidance for FY26 - Medtronic anticipates FY26 organic revenue growth of approximately 5%, with diluted non-GAAP EPS growth expected to be around 4% [23][24]